New hope for breast cancer patients with brain tumors: drug trial targets hard-to-treat spread

NCT ID NCT05866432

Recruiting now Disease control Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called datopotamab-deruxtecan (Dato-DXd) in 20 people with triple-negative breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants must have newly diagnosed or worsening brain metastases. The study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER STAGE IV

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology
RECRUITING

Vienna, State of Vienna, 1090, Austria

Contact Phone: •••-•••-•••• Email: •••••@•••••